A Phase 1/2, Open-Label, Multicenter, Non-Randomized, Safety And Activity Study Of Her-Targeted Dual Switch Car-T Cells (Bpx-603) In Subjects With Previously Treated Advanced Her2-Positive Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986207 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
Phase 1/2a First-In-Human Study Of BMS-986218 Monoclonal Antibody Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Phase 1/2 First-In-Human Study Of BMS-986249 Alone And In Combination With Nivolumab In Advanced Solid Tumors Read more
A Randomized Phase II/III Open-Label Study Of Ipilimumab And Nivolumab Versus Temozolomide In Patients With Actively Diagnosed MGMT (Tumor O-6-Methylguanine DNA Methyltransferase) Unmethylated Glioblastoma Read more
A Phase 1/2 First-In-Human Study Of BMS-986288 Alone And In Combination With Nivolumab In Advanced Malignant Tumors Read more
A Phase 2 study of Paxalisib (GDC-0084) in recurrent or refractory Primary Central Nervous System Lymphoma (PCNSL) Read more
A Phase 1/2 Study Of BMS-986340 As Monotherapy And In Combination With Nivolumab In Participants With Advanced Solid Tumors Read more
